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INTRODUCTION
Ovarian cancer is the sixth common disease which
contributes to higher death incidence in women
worlwide.1 More than 200.000 women died
because of ovarian cancer, especially in women
living in low income among developed and
developing countries.2 The highest rate of death
is located in sub-Saharan Africa, including South
Africa (40/100.000 people). In Africa, most of the
patients with ovarian cancer are diagnosed in
advanced stage disease (59.3% is diagnosed in
stage III). Whereas the decrease of ovarian cancer
incidence and mortality is documented in
developed countries, such as USA, Canada, and
Scandinavia; conversely, this documentation is
not completed in developing countries due to
the lack of efficiency from the screening pro-
gramme.3
In recent years, there is the development of
molecular biology in ovarian carcinoma to discover
number of therapeutic targets and new molecular
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Objective: To determine the expression of Phosphatase Regenera-
ting Liver-3 (PRL-3) and E-Cadherin in the epithelial ovarian cancer
on various stages and differentiation grades.
Method: This was a cross-sectional study design conducted at
Obstetrics and Gynecology Department of several teaching hos-
pitals, Faculty of Medicine Universitas Hasanuddin from January
to June 2015. The expression of PRL-3 and E-cadherin was
assessed immunohistochemically in 40 patients with epithelial
ovarian cancer including 15 patients in early stage and 25 patients
in advanced stage. We used the Fisher’s exact test with the
significance of p<0.05 for the statistical analysis. The Spearman
correlation test was used to analyze the correlation between
PRL-3 and E-cadherin expression.
Result: Our study showed no statistically significant difference of
PRL-3 expression to the stage and the differentiation degree of
epithelial ovarian cancer (p>0.05). The significant difference was
found in the expression of E-cadherin whereas the high expression
was shown at early stage than advanced stage (p<0.05). There was
no significance difference between degree of differentiation
and E-cadherin expression (p>0.05). This study also pointed out no
correlation between the expression of PRL-3 and E-cadherin in
epithelial ovarian cancer (p>0.05).
Conclusion: PRL-3 overexpression does not decrease E-cadherin
expression in epithelial ovarian cancer.
[Indones J Obstet Gynecol 2016; 4-3: 170-175]
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Abstrak
Tujuan: Menilai ekspresi Phophastase Regenerating Liver-3 (PRL-3)
dan E-cadherin dihubungkan dengan stadium dan derajat differen-
siasi kanker ovarium epitel.
Metode: Penelitian potong lintang yang dilakukan pada beberapa
rumah sakit pendidikan pada Departemen Obstetri dan Ginekologi
Fakultas Kedokteran Universitas Hasanuddin dari Januari sampai
Juni 2015. Penilaian ekspresi PRL-3 dan E-cadherin secara imunohis-
tokimia dilakukan pada 40 pasien kanker ovarium epitel (15 pasien
stadium awal, 25 pasien stadium lanjut). Data dianalisis menggu-
nakan uji Fisher’s exact dengan tingkat kemaknaan p<0,05. Uji kore-
lasi Spearman digunakan untuk menilai korelasi antara ekpresi PRL-3
dan E-cadherin pada kanker ovarium epitel.
Hasil: Penelitian kami menunjukkan tidak ada perbedaan bermakna
ekspresi PRL-3 terhadap stadium dan derajat diferensiasi kanker
ovarium epitel (p>0,05). Perbedaan bermakna ditemukan pada
ekspresi E-cadherin di mana ekspresi lebih tinggi pada stadium awal
dibandingkan stadium lanjut (p<0,05), sedangkan tidak ada perbe-
daan bermakna antara tingkat diferensiasi dan ekspresi E-cadherin
(p>0,05). Penelitian ini juga menemukan ekspresi PRL-3 tidak ber-
korelasi dengan E-cadherin pada kanker ovarium epitel (p>0,05).
Kesimpulan: Ekpresi berlebihan PRL-3 tidak menurunkan ekspresi
E-cadherin pada kanker ovarium epitel.
[Maj Obstet Ginekol Indones 2016; 4-3: 170-175]
Kata kunci: E-cadherin, kanker ovarium epitel, PRL-3
Correspondence: Risma Maharani. Department of Obstetrics and Gynecology, Dr. Wahidin Sudiro Husodo Hospital,
Telephone/mobile: 081282162999. email: reezma_dj@yahoo.com
Indones J
170  Maharani et al Obstet Gynecol
prognostic factors, such as phosphatase regenera-
ting liver-3 (PRL-3) and E-cadherin. Phosphatase
Regenerating Liver-3 is a part of the protein
tyrosine phosphatase that has a role in regulating
the intracellular growth pathway. Some studies
suggest that PRL phosphatase, especially PRL-3,
plays important function in growth, proliferation,
cell motility and invasion regulation.4 The PRL-3
also has a role in the process of carcinogenesis.
Specifically, PRL-3 is involved in the reconstruction
of the cytoskeleton, adhesion and cancer cell cycle
regulation, also epithelial-mesenchymal transition.
Through this mechanism, PRL-3 is involved in
invasion, migration, metastasis, and angiogenesis.
Higher expression of PRL-3 is associated with
tumor progression and severity of the disease. The
over expression of PRL-3 is varied based on the
type of tumor; many studies showed that tumor
metastases both in lymph nodes and other organs
would increase the PRL-3 expression extre-
mely.5
E-cadherin (E-cad), the cell adhesion molecule
plays an important role in maintaining tissue
integrity. Impaired function of E-cadherin has
often been associated with tumor formation
and invasion in vivo and in vitro.6 E-cadherin
is expressed on epithelial cells and it is important
for epithelial cells differentiation and cells adhe-
sion during embryogenesis.7 Abnormal expres-
sion of E-cadherin is associated with higher
invasiveness and poor differentiation from
several types of epithelial carcinomas.8
According to the theory above, we have not ever
reported the association between PRL-3 and
E-cadherin in epithelial ovarian cancer in Indo-
nesia, especially Makassar. Therefore, this study
aims to determine the role of PRL-3 and E-cadherin
in epithelial ovarian cancer progressivity. Further
more, we would like to assess the relationship
between the expression of PRL-3 and E-cadherin
through clinicopathological factors, as potential
target for epithelial ovarian cancer therapy.
METHODS
This cross-sectional study was conducted from
January to June 2015. Tumor tissues were collected
from 40 patients who had been undergone surgery
for epithelial ovarian carcinoma at Obstetrics and
Gynecology Department of several teaching hospi-
tals, Faculty of Medicine Universitas Hasanuddin.
The analysis of immunohistochemical was
performed at Anatomical Pathology Laboratory,
Department of Anatomical Pathology Faculty of
Medicine Universitas Hasanuddin and Pathology
Laboratory Dr. Wahidin Sudirohusodo Hospital
Makassar. We got the written informed consent
from the patients before performing this study.
Tumor tissues taken during surgery were fixed
in buffered and paraffin-embedded formalin. The
tissue blocks were cut using a microtome into 4-
m-thickness sections on silanized glasses. After
that, the tissue sections were immersed in hot
water at 40°C and dried on hot plate at 60°C for 1
hour. We would store the sections at room
temperature.
We performed the immunohistochemical analy-
sis using streptavidin-biotin-peroxidase labeled
streptavidin-biotin (Dako, Carpinteria, USA). Before
staining, the tissue sections were deparaffinized in
xylenes for 15 minutes. Then, the tissue sections
were washed with dH2O two times for 5 minutes
each and incubated with Phosphate-buffered saline
(PBS) for 5 minutes. In order to exhibit antigen, the
tissue sections were heated in an autoclave for 15
minutes in citrate buffer. The tissue sections were
cooled at room temperature for 1 hour and after
drying, they were demarcated using a pap pen.
After that, we repeated the washing with dH2O for
5 minutes and PBS for 5 minutes before incuba-
ting them into 0.3% hydrogen peroxidase for 15
minutes. After endogenous peroxidase blocked,
the tissue sections were incubated with blocking
solution for 30 minutes to block avidin contained
in the sections. The tissue sections were incu-
bated overnight at -4°C with primary PRL-3 an-
tibody (Santa Cruz) diluted 1 : 100 and E-cadhe-
rin monoclonal antibody (Biocare) diluted 1 :
100. The tissue sections would be washed three
times with dH2O before incubating with secondary
antibodies and streptavidin for 30 minutes. The
3,3’-diamino-benzidine tetrahydrocloride was used
for staining approximately 10 minutes to obtain
the staining reaction that could be detected by mi-
croscopic examination. Subsequently, the sections
were stained with hematoxylin eosin to clarify the
nucleus of a cell for 30 seconds and they were
washed with running water for 5 minutes. The
tissue sections would be dehydrated in alcohol
gradually from 70%, 80%, 90% to 100% for every
2 minutes. Then, the sections were dipped in
xylene for 5 minutes and covered with cover slip
after malinol application. The staining degree of
PRL-3 and E-cadherin expression could be seen
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from the percentage of cell group stained. The per-
centage was obtained from the sum of positive cells
in the entire field of tissue sections view examina-
tion using a light microscope.
Immunohistochemical scoring system for pro-
tein E-cadherin and PRL on epithelial ovarian can-
cer uses three parameters consisting of intensity of
expression, the percentage of positive cells, and
expression patterns. The expression of E-cadherin
is as follows: grade 1 = score 1-3; grade 2 = score
4-6; grade 3 = score 7-9; grade 4 = score 10. The
grade 1 and 2 are classified as low level of expres-
sion; while, grade 3 and 4 are classified as high
level of expression.
The Fisher’s exact test was used to analyze the
correlation between PRL-3 and E-cadherin expres-
sion with clinicopathological parameters. The cor-
relation of PRL-3 and E-cadherin expression level
with epithelial ovarian cancer was analyzed with
Pearson’s test. We used p<0.05 as statistically sig-
nificant. Data were analyzed using SPSS for win-
dows version 20.
RESULTS
We included 40 women who experienced epithelial
ovarian cancer. The youngest age was 24 and 59
years old for the oldest patients. Most of the pa-
tients were between 31-40 years old (35%) and
41-50 years old (35%). Most of them were jobless
(65%) and they had 1 to 4 children. In this study,
15 women were at early stage (37.5%) and 25
women (62.5%) were at advanced stage of the
disease. Poor differentiation degree was mostly
found in 47.5% patients (Table 1).
Table 1. Subject Characteristics
Characteristics n %
Age (years old)
 30 2 5.0
31-40 14 35.0
41-50 14 35.0
>60 10 25.0
Occupation
Jobless 26 65.0
Governmental officer 7 17.5
Private officer 7 17.5
Parity
Nulliparous 13 32.5
1-4 21 52.5
5 6 15.0
Stages
Early 15 37.5
Advanced 25 62.5
Differentiation degree
Good 11 27.5
Mild 10 25.0
Poor 9 47.5
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Figure 1. Immunohistochemical Staining of PRL-3 Expression in Epithelial Ovarian Cancer.
A = Grade I, B = Grade II, C = Grade III.
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Figure 1 showed the expression of PRL-3 in epi-
thelial ovarian cancer using immunohistochemical
staining. The PRL-3 expression at various stages
and degrees of differentiation showed no signifi-
cant difference between the expression of PRL-3 at
early stage compared to advanced stage. Apart
from that, it pointed out the similar result to
various degrees of epithelial ovarian cancer
differentiation (p> 0.05) (Table 2).
The expression of E-cadherin in epithelial ova-
rian cancer using immunohistochemical staining
was showed in Figure 2. E-cadherin expression at
various stages and degrees of differentiation was
found significantly different. High expression of
E-cadherin was observed in early stage; while, low
expression was seen in advanced stage (p<0.05).
Conversely, there was no significant difference
found between E-cadherin expression and degree
of differentiation (p>0.05) (Table 2).
Table 3. Correlation PRL-3 and E-cadherin
E-cadherin
PRL-3 rs = 0.161*
p = 0.320*
*Spearman correlation test
The statistical analysis showed no significant
association between the expression of PRL-3 and
E-cadherin in epithelial ovarian cancer (p>0.05).
Therefore, it could be inferred that the expression
of PRL-3 was not associated with the decreased
expression (down-regulation) of E-cadherin in
epithelial ovarian cancer.
DISCUSSION
This study showed the PRL-3 expression on the
primary tumor tissue from 40 samples of epithelial
ovarian cancer using the immunohistochemical
Table 2. PRL-3 and E-cadherin Expression on Stage and Differentiation Degree of Epithelial Ovarian Cancer
Variables
PRL­3
p­value* E­cadherin p­value*
Low High Low High
Stage
Early 13 (86.7) 2 (13.3) 1.000 2 (13.3) 13 (86.7) <0.001
Advanced 21 (84.0) 4 (16.0) 19 (76.0) 6 (24.0)
Differentiation degree
Good 9 (81.8) 2 (18.2) 1.000 5 (45.5) 6 (54.5) 0.727
Poor 25 (86.2) 4 (13.8) 16 (55.2) 13 (44.8)
*Fisher’s Exact
Figure 2. Immunohistochemical Staining of E-cadherin Expression in Epithelial Ovarian Cancer.
A = Grade I, B = Grade II, C = Grade III.
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method. Positive expression of PRL-3 was found in
34 samples of primary ovarian tumors. This study
found no significant association between PRL-3
expression in primary tumor and epithelial ovarian
cancer stage. The similar result reported by Reich,
et al. stated that there was no significant difference
between the expression of PRL-3 and ovarian
cancer stage.9 In contrast, Polato, et al. found PRL-3
expression was high at an advanced stage than
early stage.10 It could be due to the sample size
which involved 61 samples in stage I and 23 sam-
ples in stage III. Meanwhile, Reich, et al. study
indicated fewer sample for early stage than
advanced stage.
The PRL-3 expression was not significantly
different in degrees of differentiation. Similar
finding was reported by Reich, et al. and Polato, et
al. studies which stated that there was no associa-
tion between the expression of PRL-3 and degree
of differentiation. Interestingly, Liu, et al. found
up-regulation of PRL-3 ovarian cancer only
occurred in differentiated cancer cells.11
E-cadherin plays a role in maintaining cell adhe-
sion to prevent tumor cell invasion. E-cadherin me-
diated intercelullar adhesion that connects to cy-
toskeleton and cathenin as an intracellular binding
protein. Low expression of E-cadherin will lead to
detach tumor cells and attach to the matrix com-
ponent resulting in migration and metastasis.
E-cadherin tumor suppression gene has been
widely studied in tumorigenesis. The interaction
between E-cadherin molecules is crucial to the
formation of adhesion among cells and maintain
the cells adhesion. The loss of E-cadherin is asso-
ciated with the transition from benign lesions to
the invasive and metastatic lesions.12
In this study, the protein E-cadherin was
expressed in all primary epithelial ovarian cancer.
Although, there was no significant difference of
E-cadherin expression in various degrees of
differentiation, there were statistically significant
difference of the E-cadherin expression in epithe-
lial ovarian cancer stage. High expression of
E-cadherin was found in early stage than advanced
stage. Study by Faleiro-Rodrigues, et al. revealed a
significant decreased expression of E-cadherin
based on FIGO staging and they showed no corre-
lation to tumor differentiation.13 In another study
on the expression of E-cadherin and its relation-
ship with ovarian cancer showed that a decreased
expression of E-cadherin was associated with the
severity of ovarian cancer based on FIGO staging,
lymph node metastasis, and degree of tumor dif-
ferentiation. This result would like to reveal that
the expression of E-cadherin tended to decrease
with the increasing of stage disease and poorly
differentiated cancer cells.14
This is the first study that reported association
between the expression of PRL-3 and E-cadherin.
We revealed that the increased levels of PRL-3 did
not affect the levels of E-cadherin and also vice
versa. Our result was contrary with the result by
Liu, et al. Liu found that the PRL-3 increased the
epithelial mesenchymal transition (EMT) by down-
regulated expression of E-cadherin. The EMT
enhancement mechanism caused by PRL-3 was still
unknown. Liu, et al. found that PRL-3 might im-
prove the EMT in colorectal cancer cells SW480
models deficient in the expression of E-cadherin in
vivo and in vitro. The overexpression of PRL-3 or
SW480 cell solution was injected subcutaneously
in nude mice. The result of immunohistochemical
analysis of tumor samples from nude mice showed
that the PRL-3 increased the up-regulation of
mesenchymal marker vimentin and down-regula-
tion epithelial marker of E-cadherin and cytoke-
ratin.11 Guo, et al. study on the ability of PRL-3
triggering tumor angiogenesis reported that sub-
cutaneous injection of PRL-3 in nude mice led to
increase formation of endothelial cells in the tumor
mass.5 In contrast, Sundfeldt, et al. revealed that
the down-regulation or abnormal expression of
E-cadherin was associated with highly invasive
capacity and poorly differentiated epithelial ova-
rian carcinoma.6
CONCLUSION
Our study has shown that E-cadherin plays an im-
portant role in the progression of epithelial ovarian
cancer. This suggests that E-cadherin might have
therapeutic value and a potential biomarker in the
progression of ovarian cancer. The PRL-3 and
E-cadherin also plays a role in ovarian cancer
metastasis. Therefore, we need to investigate the
role of PRL-3 and E-cadherin in the process of
ovarian cancer metastases for future studies.
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